Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Should l Buy TYRA?
Source: PRnewswire
Dabogratinib Development: Tyra Biosciences has initiated the BEACH301 Phase 2 clinical trial for dabogratinib, an oral FGFR3-selective inhibitor, aimed at treating children with achondroplasia, a common form of dwarfism.
Trial Details: The study will enroll children aged 3 to 10 with open growth plates and will assess safety, tolerability, and growth velocity changes over a planned duration of up to 12 months.
Community Impact: The dosing of the first child in the trial is seen as a significant milestone for both Tyra and the achondroplasia community, highlighting the need for targeted treatment options.
Company Background: Tyra Biosciences focuses on precision medicines targeting FGFR biology, with dabogratinib being their lead candidate, also under investigation for other conditions like cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TYRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TYRA
Wall Street analysts forecast TYRA stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.750
Low
30.00
Averages
33.75
High
37.00
Current: 33.750
Low
30.00
Averages
33.75
High
37.00
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tyra Biosciences Q4 Earnings Report Analysis
- Disappointing Earnings: Tyra Biosciences reported a Q4 GAAP EPS of -$0.57, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Net Loss Reported: The company recorded a net loss of $33.8 million, reflecting high costs in R&D and operations, which may lead to increased future financing needs and impact shareholder returns.
- Cash Position: As of the end of the reporting period, Tyra Biosciences held $256 million in cash, cash equivalents, and marketable securities, providing a solid liquidity position, yet ongoing losses may restrict future investment and expansion capabilities.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance towards Tyra Biosciences' future performance, potentially leading to stock price volatility and a decline in market confidence.
See More
Tyra Biosciences Launches 'Dabogratinib 3x3' Strategy for Blockbuster Indications
- New Strategy Launch: Tyra Biosciences has unveiled its 'dabogratinib 3x3' strategy, aiming to conduct three late-stage clinical studies in low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH), demonstrating the company's strategic focus in precision medicine.
- Clinical Data Progress: Interim Phase 2 data readouts for SURF302 are expected by the end of 1H 2026, with BEACH301 scheduled for 2H 2026, indicating Tyra's proactive advancement in clinical trials that may lay the groundwork for future regulatory submissions.
- Strong Financial Position: As of Q4 2025, Tyra reported cash, cash equivalents, and marketable securities totaling $256 million, providing a runway through at least 2027, showcasing its financial resilience in supporting R&D and market expansion.
- Significant Market Potential: By focusing on selective FGFR3 inhibition, Tyra aims to address high unmet medical needs while creating substantial long-term value, underscoring its strategic importance and competitive edge in the biotechnology sector.
See More
Tyra Biosciences to Present New Research at ASCO GU Conference
- Research Presentation: Tyra Biosciences announced that two abstracts have been accepted for the 2026 ASCO GU Cancer Symposium, showcasing its latest advancements in FGFR biology, which is expected to enhance the company's reputation in precision medicine.
- Clinical Trial Progress: One study involves ctDNA monitoring of FGFR3-altered metastatic urothelial cancer patients treated with dabogratinib (formerly TYRA-300), demonstrating the company's innovative capabilities in cancer treatment.
- Multicenter Study: The other study is a Phase 2 multicenter, open-label trial evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate-risk non-muscle invasive bladder cancer, further solidifying TYRA's clinical standing in oncology.
- Future Development Potential: TYRA's oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor, is undergoing multiple Phase 2 clinical studies, indicating the company's broad application prospects in FGFR-targeted therapies.
See More
Tyra Biosciences Presents Two Abstracts at ASCO GU Symposium
- Abstract Presentation: Tyra Biosciences announced the acceptance of two abstracts for the 2026 ASCO GU Symposium, focusing on research related to FGFR3-altered metastatic urothelial cancer and low-grade non-muscle invasive bladder cancer, highlighting the company's advancements in FGFR biology.
- Clinical Trial Details: The first abstract pertains to the SURF301 trial, which monitors ctDNA in patients treated with dabogratinib for FGFR3-altered metastatic urothelial cancer, while the second focuses on the SURF302 trial evaluating the efficacy and safety of dabogratinib in low-grade non-muscle invasive bladder cancer patients.
- Conference Schedule: Both studies will be presented during the poster session on February 27, 2026, from 11:30 AM to 12:45 PM PST, enhancing Tyra's academic influence in the oncology field.
- Future Development Directions: Dabogratinib, as a potential first-in-class selective FGFR3 inhibitor, is undergoing multiple clinical studies, showcasing Tyra's robust R&D capabilities and market potential in precision medicine.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Tyra Biosciences Director Sells 246,871 Shares for $5 Million
- Insider Transaction: On November 21, Tyra Biosciences Director Robert J. More sold 246,871 shares at $20.25 each for a total of $5 million, indicating confidence in the company's future despite being part of a Rule 10b5-1 trading plan.
- Shareholding Status: Post-transaction, More retains 3,833,425 shares valued at approximately $77.6 million at current prices, reflecting his ongoing belief in the company's long-term prospects.
- Market Performance: As of December 23, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, indicating strong market optimism regarding its growth potential.
- Financial Condition: Although the third-quarter report showed slight increases in R&D and SG&A expenses along with a higher net loss, analysts generally rate Tyra as a moderate buy, suggesting confidence in its future growth despite its early-stage status.
See More
Tyra Biosciences Q4 Earnings Report Analysis
- Disappointing Earnings: Tyra Biosciences reported a Q4 GAAP EPS of -$0.57, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Net Loss Reported: The company recorded a net loss of $33.8 million, reflecting high costs in R&D and operations, which may lead to increased future financing needs and impact shareholder returns.
- Cash Position: As of the end of the reporting period, Tyra Biosciences held $256 million in cash, cash equivalents, and marketable securities, providing a solid liquidity position, yet ongoing losses may restrict future investment and expansion capabilities.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance towards Tyra Biosciences' future performance, potentially leading to stock price volatility and a decline in market confidence.
See More
Tyra Biosciences Launches 'Dabogratinib 3x3' Strategy for Blockbuster Indications
- New Strategy Launch: Tyra Biosciences has unveiled its 'dabogratinib 3x3' strategy, aiming to conduct three late-stage clinical studies in low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH), demonstrating the company's strategic focus in precision medicine.
- Clinical Data Progress: Interim Phase 2 data readouts for SURF302 are expected by the end of 1H 2026, with BEACH301 scheduled for 2H 2026, indicating Tyra's proactive advancement in clinical trials that may lay the groundwork for future regulatory submissions.
- Strong Financial Position: As of Q4 2025, Tyra reported cash, cash equivalents, and marketable securities totaling $256 million, providing a runway through at least 2027, showcasing its financial resilience in supporting R&D and market expansion.
- Significant Market Potential: By focusing on selective FGFR3 inhibition, Tyra aims to address high unmet medical needs while creating substantial long-term value, underscoring its strategic importance and competitive edge in the biotechnology sector.
See More
Tyra Biosciences to Present New Research at ASCO GU Conference
- Research Presentation: Tyra Biosciences announced that two abstracts have been accepted for the 2026 ASCO GU Cancer Symposium, showcasing its latest advancements in FGFR biology, which is expected to enhance the company's reputation in precision medicine.
- Clinical Trial Progress: One study involves ctDNA monitoring of FGFR3-altered metastatic urothelial cancer patients treated with dabogratinib (formerly TYRA-300), demonstrating the company's innovative capabilities in cancer treatment.
- Multicenter Study: The other study is a Phase 2 multicenter, open-label trial evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate-risk non-muscle invasive bladder cancer, further solidifying TYRA's clinical standing in oncology.
- Future Development Potential: TYRA's oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor, is undergoing multiple Phase 2 clinical studies, indicating the company's broad application prospects in FGFR-targeted therapies.
See More
Tyra Biosciences Presents Two Abstracts at ASCO GU Symposium
- Abstract Presentation: Tyra Biosciences announced the acceptance of two abstracts for the 2026 ASCO GU Symposium, focusing on research related to FGFR3-altered metastatic urothelial cancer and low-grade non-muscle invasive bladder cancer, highlighting the company's advancements in FGFR biology.
- Clinical Trial Details: The first abstract pertains to the SURF301 trial, which monitors ctDNA in patients treated with dabogratinib for FGFR3-altered metastatic urothelial cancer, while the second focuses on the SURF302 trial evaluating the efficacy and safety of dabogratinib in low-grade non-muscle invasive bladder cancer patients.
- Conference Schedule: Both studies will be presented during the poster session on February 27, 2026, from 11:30 AM to 12:45 PM PST, enhancing Tyra's academic influence in the oncology field.
- Future Development Directions: Dabogratinib, as a potential first-in-class selective FGFR3 inhibitor, is undergoing multiple clinical studies, showcasing Tyra's robust R&D capabilities and market potential in precision medicine.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Tyra Biosciences Director Sells 246,871 Shares for $5 Million
- Insider Transaction: On November 21, Tyra Biosciences Director Robert J. More sold 246,871 shares at $20.25 each for a total of $5 million, indicating confidence in the company's future despite being part of a Rule 10b5-1 trading plan.
- Shareholding Status: Post-transaction, More retains 3,833,425 shares valued at approximately $77.6 million at current prices, reflecting his ongoing belief in the company's long-term prospects.
- Market Performance: As of December 23, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, indicating strong market optimism regarding its growth potential.
- Financial Condition: Although the third-quarter report showed slight increases in R&D and SG&A expenses along with a higher net loss, analysts generally rate Tyra as a moderate buy, suggesting confidence in its future growth despite its early-stage status.
See More
